Preclinical News and Research

RSS

Zoledronic acid may benefit post-menopausal women with breast cancer

A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.

26 Sep 2011

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.

23 Sep 2011

CoPlex, Hawthorn sign license agreement for hawAD14 Alzheimer's drug

CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

23 Sep 2011

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival.

23 Sep 2011

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

23 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fund a pre-clinical trial evaluating the safety and efficacy of a gene therapy treatment for X-linked Retinoschisis (XLRS), a genetic eye disease affecting over 35,000 patients in the US and Europe.

22 Sep 2011

NIH-funded project to develop new class of tissue regeneration therapeutics

The National Institutes of Health (NIH) has awarded nearly $2 million to researchers at the Georgia Institute of Technology and Emory University to develop a new class of therapeutics for treating traumatic injuries and degenerative diseases.

22 Sep 2011

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that in a rodent contusion model of SCI the Company's proprietary biopolymer scaffold showed positive preliminary data that indicate a therapeutic effect.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

20 Sep 2011

Nuevolution announces collaboration in drug discovery with Boehringer Ingelheim

Nuevolution A/S today announced that it has entered into collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics® drug discovery technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance drug candidates against drug targets of interest to Boehringer Ingelheim.

20 Sep 2011

SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS

Mayo Clinic's campus in Florida has entered into a collaborative and sponsored research agreement with SK Biopharmaceuticals of Seoul, South Korea, with the goal of developing new treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The collaboration marks a new approach to combating a disease that has proved difficult to treat in recent clinical trials.

20 Sep 2011

Calgary researchers discover new class of anti-inflammatory agents

By using a mouse model of inflammation researchers at the University of Calgary have discovered a new class of molecules that can inhibit the recruitment of some white blood cells to sites of inflammation in the body.

20 Sep 2011

Preclinical News and Research

Zoledronic acid may benefit post-menopausal women with breast cancer

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

CoPlex, Hawthorn sign license agreement for hawAD14 Alzheimer's drug

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

NIH-funded project to develop new class of tissue regeneration therapeutics

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Nuevolution announces collaboration in drug discovery with Boehringer Ingelheim

SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS

Calgary researchers discover new class of anti-inflammatory agents

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics